Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections

Here, the authors identify interleukin-3 as a predictive marker for severity and outcome of SARS-CoV-2 infection in a multi-center, prospective study and find that patients with severe COVID-19 have reduced circulating plasmacytoid dendritic cell levels compared to non-severe COVID-19 patients.

Guardado en:
Detalles Bibliográficos
Autores principales: Alan Bénard, Anne Jacobsen, Maximilian Brunner, Christian Krautz, Bettina Klösch, Izabela Swierzy, Elisabeth Naschberger, Malgorzata J. Podolska, Dina Kouhestani, Paul David, Torsten Birkholz, Ixchel Castellanos, Denis Trufa, Horia Sirbu, Marcel Vetter, Andreas E. Kremer, Kai Hildner, Andreas Hecker, Fabian Edinger, Matthias Tenbusch, Petra Mühl-Zürbes, Alexander Steinkasserer, Enrico Richter, Hendrik Streeck, Marc M. Berger, Thorsten Brenner, Markus A. Weigand, Filip K. Swirski, Georg Schett, Robert Grützmann, Georg F. Weber
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Q
Acceso en línea:https://doaj.org/article/da75b62b7c584d48a9ba0f701d8cd0cf
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Here, the authors identify interleukin-3 as a predictive marker for severity and outcome of SARS-CoV-2 infection in a multi-center, prospective study and find that patients with severe COVID-19 have reduced circulating plasmacytoid dendritic cell levels compared to non-severe COVID-19 patients.